Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.

Employees

261

Sector

Real Estate Development & Operations

More about the company

Quotes

Date	Price	Change	Volume
24/08/26	₹91.61	-1.21%	16,545
21/08/26	₹92.73	+1.42%	56,656
20/08/26	₹91.43	+3.05%	75,598
19/08/26	₹88.72	-1.08%	29,258
18/08/26	₹89.69	-0.40%	51,164

Delayed Quote Bombay S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed Bombay S.E. 10:21:58 24/08/2026 +04			5-day change	1st Jan Change
91.61 ^INR	-1.21%		+1.73%	-9.35%

08-11	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
05-19	Alembic Limited Recommends Dividend for the Year Ended March 31, 2026	CI

Market Cap	23.81B 249M 213M 199M 183M 343M 347M 2.36B 919M 11.96B 934M 914M 39.56B	P/E 2025	8.14x	P/E 2026	5.74x
Enterprise Value	22.94B 240M 205M 192M 176M 330M 334M 2.27B 885M 11.52B 900M 881M 38.11B	EV / Sales 2025	11.2x	EV / Sales 2026	7.22x
Free-Float	27.58%	Yield 2025	2.44%	Yield 2026	3.38%

08-11	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
05-19	Alembic Limited Recommends Dividend for the Year Ended March 31, 2026	CI
05-19	Alembic Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
04-23	Alembic Pharmaceuticals Incorporates Philippines Subsidiary	MT
02-12	Alembic Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
11-27	Bajaj Healthcare Limited Appoints Shreekumar Shankarnarayan Nair as Chief Operating Officer, Effective November 27, 2025	CI
11-17	Accenture Invests in AI Marketing Intelligence Platform Alembic	MT
11-17	Alert wrongly tagged to India's Alembic withdrawn	RE
11-17	Alembic raises $145 million to accelerate enterprise adoption of causal AI	RE
11-17	Accenture invests in Alembic to reinvent marketing measurement with data and Causal AI	RE
11-11	Alembic Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
12/08/25	Alembic Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
12/08/25	Alembic Limited Announces Resignation of Malika Amin as CEO, Effective 1 January, 2026	CI

04/07/25	Alembic : Annual Report 2024-25	PU
27/05/25	Supreme Court Rules Against Ex-Post Facto Environment Clearance	AQ
14/08/24	Alembic Pharmaceuticals announces USFDA Dabigatran Etexilate Capsules, 110 mg	AQ
25/07/24	Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg	AQ
07/08/23	Alembic Pharmaceuticals - Revenue up 18% to Rs. 1486 crores in Q-1 FY24	AQ

Alembic Limited Stock

Stocks

ALEMBICLTD

INE426A01027

Real Estate Development & Operations

Valuation: Alembic Limited

Chart: Alembic Limited

Latest news : Alembic Limited

Press Releases: Alembic Limited

Quotes and Performance

Course Extremes

Managers and Directors: Alembic Limited

Other Real Estate Development & Operations

Financials

Company Profile

Quotes

1 day	-1.21%
1 week	+1.73%
Current month	+0.43%
1 month	+4.43%
3 months	+4.42%
6 months	-0.93%
Current year	-9.35%

1 week	87.25	93.93
1 month	82.75	93.93
Current year	70.64	104.25
1 year	70.64	108.55
3 years	70.64	169
5 years	55.52	169
10 years	25	169

Manager	Title	Age	Since
Udit Chirayu Amin CEO	Chief Executive Officer	46	01/10/2025
Rasesh J. Shah DFI	Director of Finance/CFO	-	13/08/2014
Kevalkumar B. Thakkar CMP	Compliance Officer	-	01/09/2023

Director	Title	Age	Since
Chirayu Ramanbhai Amin CHM	Chairman	78	20/08/1967
Malika Chirayu Amin BRD	Director/Board Member	71	02/07/1988
Udit Chirayu Amin BRD	Director/Board Member	46	24/04/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALEMBIC LIMITED	-1.21%	+1.73%	-12.79%	+14.84%	249M
SUN HUNG KAI PROPERTIES LIMITED	-1.01%	+8.36%	+35.47%	+42.22%	47.38B
CHINA RESOURCES LAND LIMITED	-3.22%	+0.82%	+7.81%	+7.67%	32.18B
MITSUBISHI ESTATE CO., LTD.	+1.08%	+1.41%	+17.50%	+110.09%	27.9B
EMAAR PROPERTIES	+0.91%	+0.18%	-25.66%	+57.71%	26.37B
MITSUI FUDOSAN CO., LTD.	+1.30%	+4.69%	-5.86%	+48.05%	25.36B
CK ASSET HOLDINGS LIMITED	-0.25%	+2.83%	+26.27%	+10.93%	21.12B
ALPHA DHABI HOLDING	+0.80%	-1.05%	-34.86%	-62.57%	20.33B
CHINA OVERSEAS LAND & INVESTMENT LIMITED	-1.84%	+3.06%	-4.22%	-10.66%	19.68B
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	+1.71%	+1.01%	+7.66%	+90.73%	19.4B
Average	-0.20%	+2.84%	+1.13%	+30.90%	24B
Weighted average by Cap.	-0.26%	+3.18%	+6.26%	+35.72%

	2025	2026
Net sales	2.22B 23.19M 19.87M 18.59M 17.01M 31.93M 32.35M 220M 85.64M 1.11B 87.08M 85.18M 3.69B	2.4B 25.08M 21.49M 20.1M 18.4M 34.54M 34.99M 238M 92.63M 1.21B 94.18M 92.13M 3.99B
Net income	3.11B 32.47M 27.81M 26.03M 23.82M 44.71M 45.3M 307M 120M 1.56B 122M 119M 5.16B	3.17B 33.17M 28.41M 26.59M 24.34M 45.67M 46.28M 314M 122M 1.59B 125M 122M 5.27B
Net Debt	-438M -4.58M -3.92M -3.67M -3.36M -6.31M -6.39M -43.37M -16.91M -220M -17.2M -16.82M -728M	-874M -9.13M -7.82M -7.32M -6.7M -12.58M -12.74M -86.5M -33.73M -439M -34.3M -33.55M -1.45B